Bind Therapeutics Inc., of Cambridge, Mass., said New York-based Pfizer Inc. prevailed at a Section 363 auction to purchase substantially all of Bind’s assets. The winning bid of $40 million, subject to U.S. Bankruptcy Court approval for which a hearing is scheduled to take place on July 27, 2016, was selected as the highest and best bid. Nanocarrier Co. Ltd., of Chiba, Japan, has been selected as the back-up bidder. Bind, which filed for Chapter 11 earlier this year, plans to disclose additional terms of its agreement with Pfizer upon court approval. Bind’s assets include its nanoparticle-based platform technology that creates Accurins, particles designed to encapsulate drugs and direct the payload to specific disease cells.